We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.875 | 2.75 | 3.00 | 2.875 | 2.875 | 2.88 | 973,172 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.19 | 136.8M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/6/2023 08:21 | 60% down, and nice start lol | zen12 | |
19/6/2023 08:15 | Nice start to the day! | jpuff | |
19/6/2023 07:05 | Allergy Therapeutics PLC Interim Results and Lifting Suspension in Trading 19/06/2023 7:01am UK Regulatory (RNS & others) Allergy Therapeutics (LSE:AGY) Intraday Stock Chart Monday 19 June 2023 Click Here for more Allergy Therapeutics Charts. TIDMAGY RNS Number : 0740D Allergy Therapeutics PLC 19 June 2023 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company" or the "Group") Interim Results for the six months ended 31 December 2022 and Lifting of Suspension in Trading 19 June 2023: Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2022 and expected restoration of trading in the Company's ordinary shares on AIM with effect from 7.30am today . | wizzkid211 | |
09/6/2023 08:59 | When I read these RNS of this company and this manager I am in conflict with two opposing deep personal feelings. I don't know whether to laugh at how this company can boast of presenting studies with a scientific value close to zero as posters at the most important scientific congress in the sector: scientific value 0.000001. Or to organize a symposium essentially made up of promises that this company, I remember close to being financially insolvent, promises it NEVER kept. The other conflicting feeling is irritation. Because this manager and this company consider us ignorant fools. Tick ,tick,tick. | beccasan | |
09/6/2023 08:03 | Positive news this morning and more evidence to me as to why this is worth fighting for.Tick tick, the end of June.Impo | jimmyloser | |
07/6/2023 08:33 | The clock is certainly ticking and with each passing day it seems to tick a little louder. Where are the RNS's?What a mess we appear to be in, not at all Allergy T. as we know it.However I remain (possibly naively) positive and mildly optimistic on the potential and outlook.Read the reports on both of the trials and it becomes clearer as to why they won't just let this go. They are sitting on potentially several multi million dollar blockbusters.I like everyone else don't like this current situation but expect and hope that they can and will get their ducks in a row and start the long road back to gaining our credibility back.We need to start the news flow soon but of course, we all know that.ImpoJl | jimmyloser | |
26/5/2023 16:10 | I hate to say it, but I told you all this would happen. | coinbase | |
20/4/2023 07:32 | What is the full allowance based on? Is it as much as your existing shares or x amount more? | amishp67 | |
19/4/2023 23:24 | Gradually recovering my losses with I3e 10% divided a year.monthly dividends Profitable company. Growing T/o eventually | genises | |
19/4/2023 21:37 | Hi. Could somebody kindly explain to me what is going to happen now. I currently hold about 800 shares. | scrappy86 | |
19/4/2023 18:42 | I am voting for all resolutions and will take up my full allowance. Yesterday is dead and gone! impo | jimmyloser | |
19/4/2023 07:13 | Brilliant.. now I might get to close at 1.1p Instead of 0.1p!A bunch of morons for what they are doing here | amishp67 | |
14/4/2023 19:47 | And don't forget there will be nearly five billion confetti shares in circulation soon for this tiny business. It has 0.1p not 10p a share written all over it - with yet more funding required in the near term foreseeable future. I'm ashamed to say I hold. | jpuff | |
14/4/2023 16:38 | I don't understand how it is possible to find positive aspects in this affair. I don't understand how one can hope for the pivotal studies to be successful when the R&D department of this company has never produced a useful clinical study. Never. Ever and never. Not even for key and established products, thus a real pipe dream for a complex and potentially dangerous vaccine for the treatment of peanut allergy. As for business, all European countries are phasing out NPP vaccines from the market and this company has not been able to register a single product to the GCP standards required today. It only has a few vaccines registered here and there with very old procedures from over 20 years ago, when everything and the opposite of everything was registered and which will not be renewed. Vaccines registered in the last 15 years according to GCP standards: zero, zero, zero. Finally, most interesting and most important of all, this management, in all these years has not been able to produce a serious, sustainable and credible industrial development plan that has not always, and I always say, despised itself and its shareholders. Only the naive or those with exclusively personal or personalistic ulterior motives can still believe in this project. | beccasan | |
14/4/2023 16:35 | Jpuff, I fully agree. | beccasan | |
13/4/2023 07:59 | Folk seem to be talking as if the trials are definitely going to be positive. If that were the case we wouldn't be bankrupt with a 1p rescue bid as a punt. This is a very high risk new business - essentially a punt or wild bet! | jpuff | |
12/4/2023 23:08 | A profitable company for several years with two ground breaking trials to A company who requires 40 million with shareholders left with a value of 1p a share. The CEO should retire as he the main man who has led the investors to this debacle. Not fit to be running a company. All to happen before the ground breaking trials are completed. Wonder how much the company would be worth when positive results come out | genises | |
12/4/2023 21:59 | I agree with you 1kckeith, if we are not to be wiped out there is no alternative but to follow the money. There seem to be two things to consider, firstly, all that has gone before has to be put out of one’s mind and the fact that we have all probably lost a great deal of our original investment is history. Secondly, the company is now effectively controlled by, I would suspect, a couple of pretty sharp private equity/ venture capital investors. It is not in their interest to turn the established order upside down right now but I would guess their hand are very much on the controls and when the time is right I hope and believe they will put in people better able to achieve their objectives than the skeleton crew who are currently supposedly at the helm. They will be keen to get through this time without any further tsunamis. So, we may well now have an opportunity to venture a penny a share with the potential of something better so long as the wheels don’t come off the cash flow projections in the coming fairly precarious months. One aside but nonetheless quite an interesting aspect is that the Company no longer has any charges over its assets, following the recent removal of the NatWest fixed and floating charge. It’s not often that a company teaters on the edge of bankruptcy with wholly unencumbered assets. This situation will presumably change as soon as the investors put up their temporary loan capital. If things then go wrong for any reason and there is a breach in the covenant conditions you can be sure they will swoop and take 100% control wiping out the minorities at a stroke. This should be more difficult for them to do once the new shares have all be subscribed but the the documents would have to be examined very carefully to establish whether that is the case. Nil desperandum | stablehound |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions